APELLIS PHARMACEUTICALS, INC.
Clinical trial NCT03531255 updates: 1. enrollment: 160 → 137 participants 2. enrollment type: ESTIMATED → ACTUAL
Clinical trial NCT03531255 updates: 1. enrollment: 160 → 137 participants 2. enrollment type: ESTIMATED → ACTUAL
Clinical trial NCT06541145 updates: 1. status: RECRUITING → COMPLETED 2. completion date: 2026-06-01 → 2024-10-18 3. primary completion date: 2026-04-01 → 2024-10-18 4. enrollment: 20 → 1 participants 5. enrollment type: ESTIMATED → ACTUAL
Clinical trial NCT04403022 updates: 1. allocation: NA → NON_RANDOMIZED 2. intervention model: SINGLE_GROUP → PARALLEL
Clinical trial NCT05184556: status: ACTIVE_NOT_RECRUITING → COMPLETED.
Clinical trial NCT05333068 updates: 1. primary completion date: 2026-03-16 → 2026-09-16 2. enrollment: 1222 → 1223 participants 3. enrollment type: ESTIMATED → ACTUAL
Clinical trial NCT06672978: status: RECRUITING → ACTIVE_NOT_RECRUITING.
Clinical trial NCT07290257: enrollment: 100 → 230 participants.
Clinical trial NCT06862791 updates: 1. status: ACTIVE_NOT_RECRUITING → COMPLETED 2. completion date: 2026-05-25 → 2026-05-11 3. primary completion date: 2026-05-25 → 2026-05-11
KBRA Assigns Rating to Blue Owl Technology Finance Corp.s $500 Million Senior Unsecured Notes due 2029
Clinical trial NCT06411249: allocation: NON_RANDOMIZED → NA.